Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

Status Recruiting

Clinical Trial Summary

The aim of this study was to observe the clinical efficacy and safety of rituximab (RTX) combination with telitacicept (TA) in patients of systemic lupus erythematosus secondary antiphospholipid syndrome (APS).

Clinical Trial Description

In this multicenter, prospective, observational study, 80 patients with SLE Secondary APS patients were enrolled. RTX alone or its continuation with TA was observed for 24weeks，and extended for another 24 weeks. At week 12, the RTX group could be converted to the combination group. The primary end point was the response rate of total antiphospholipid antibody (aPL) at week 12. The secondary end points included the decline rate and value of aPL antibody, aGAPSS score, remission degree of specific clinical indicators, changes in SLE disease activity in SAPS group, and drug safety at week 12 and week 24. ;

Study Design

Related Conditions & MeSH terms

Antiphospholipid Syndrome

Clinical Trial Details

NCT number	NCT05644210
Study type	Observational
Source	Qilu Hospital of Shandong University
Contact	Shu Qiang, Dr.
Phone	0086-0531-82169654
Email	shuqiang@sdu.edu.cn
Status	Recruiting
Phase
Start date	October 1, 2022
Completion date	December 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01475149` - Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)	N/A
Completed	`NCT00537290` - A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome	Phase 2
Recruiting	`NCT00616317` - Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
Recruiting	`NCT00198068` - Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Completed	`NCT00180817` - Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.
Completed	`NCT03682419` - Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)	N/A
Not yet recruiting	`NCT03303508` - Measurement of Anti-dsDNA by Both CLIFT & ELISA	N/A
Recruiting	`NCT04262492` - International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
Withdrawn	`NCT00180778` - Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss	Phase 1/Phase 2
Enrolling by invitation	`NCT05583305` - Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome
Recruiting	`NCT02303171` - Use of Warfarin After the First Trimester in Pregnant Women With APS	Phase 4
Completed	`NCT00674297` - Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients	Phase 2
Recruiting	`NCT05859997` - Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases	N/A
Recruiting	`NCT06373003` - Negative Antiphospholipid Syndrome: a Multicentric Study
Recruiting	`NCT06373926` - Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome	N/A
Recruiting	`NCT01818505` - The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome	N/A
Completed	`NCT00878137` - Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin	N/A
Completed	`NCT01104337` - Drug Interaction Between Paracetamol and Warfarin	Phase 4
Completed	`NCT05313048` - Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination
Recruiting	`NCT03890601` - New Biological Tests in Patients With Antiphospholipid Antibodies